STAT+: Newer GLP-1s, pushback on research cuts, and a protest
Decision brief
Answer first · skim in under a minute
At the ADA conference, newer GLP-1s were highlighted alongside growing pushback against research funding cuts and a related protest. This article analyzes the developments and their impact on pharma strategy.
STAT Newer GLP-1s pushback research themes collided at the 2026 American Diabetes Association meeting: next-generation incretin data kept raising the competitive bar, while NIH budget papers showing a proposed multi-billion-dollar program-level cut intensified concern about the academic engine that feeds metabolic discovery.
Contents10 sections
Key Takeaways
- SURMOUNT-5 (NCT05822830) reported 72-week mean weight loss of 20.2% on tirzepatide versus 13.7% on semaglutide in obesity without diabetes.
- FDA already cleared tirzepatide (Zepbound) for chronic weight management, anchoring commercial expectations for dual GIP/GLP-1 agonists.
- NIH’s FY 2026 CJ overview requested $27.9 billion, about $18.1 billion below the prior CR baseline, while enacted FY 2026 program-level funding is described as $47.5 billion in NIH Guide notice NOT-OD-26-059.
- For BD teams, GLP-1 differentiation is accelerating even as partnership and investigator-sponsored research capacity faces budget uncertainty.
What newer GLP-1 data raised the competitive bar?
Obesity and diabetes sessions continue to revolve around how far next-wave incretins can beat first-generation GLP-1 receptor agonists on weight, glycemic control, and tolerability. The clearest published head-to-head signal is SURMOUNT-5.
In the New England Journal of Medicine report, tirzepatide delivered a least-squares mean 20.2% weight reduction at week 72 versus 13.7% with semaglutide (P<0.001) among 751 randomized adults with obesity without type 2 diabetes.
How does FDA labeling frame the commercial baseline?
Tirzepatide’s U.S. obesity franchise rests on the FDA approval of Zepbound for chronic weight management in adults with obesity, or overweight plus at least one weight-related condition, as an adjunct to diet and activity.
The agency’s approval notice summarized pivotal randomized evidence with statistically significant weight reduction versus placebo after 72 weeks across tested doses, including an average 18% loss at the highest approved 15 mg weekly dose in the larger trial of adults without diabetes. See the FDA announcement.
Where is the trial evidence registered?
SURMOUNT-5 is registered as NCT05822830 on ClinicalTrials.gov. Registry transparency matters for competitive intelligence because dose titration rules, exclusion criteria, and rescue therapy policies often explain why conference posters look stronger than label claims.
Portfolio teams should separate conference abstracts from peer-reviewed primary endpoints before revising peak-sales models for oral GLP-1 candidates still in late-stage development.
What NIH budget papers explain the research-cuts pushback?
Attendee frustration about federal research capacity tracks to public NIH budget materials, not rumor. The NIH FY 2026 Congressional Justification overview requested a $27.9 billion program level, described as an $18.1 billion reduction from a $46.0 billion FY 2025 CR baseline.
Separately, NIH Guide notice NOT-OD-26-059 states that the Consolidated Appropriations Act, 2026 provided a 1% increase to $47.5 billion in program-level funding. The gap between the proposed request and enacted path is the policy uncertainty academic partners keep citing.
Implications for pharma strategy teams
Commercial GLP-1 competition is intensifying on efficacy deltas measured in percentage points of body-weight loss. At the same time, early discovery and translational collaborations depend on NIH-funded labs remaining solvent and staffed.
BD groups should dual-track diligence: (1) incretin differentiation versus tirzepatide/semaglutide benchmarks, and (2) university alliance risk if grant timing slows. Medical affairs should avoid over-claiming conference protest narratives that lack primary documentation.
What remains unproven after ADA week?
SURMOUNT-5 does not prove that every next-gen oral or amylin combination will beat injectable dual agonists. Long-term cardiovascular outcomes, adherence after dose escalation, and real-world discontinuation rates still drive net clinical benefit more than a single 72-week percent-weight figure.
Likewise, a proposed NIH cut in a Congressional Justification is not the same as an enacted appropriation. Until FY 2026 operating plans settle, treat academic capacity risk as a scenario input, not a binary shutdown forecast.
Related NovaPharma coverage
- Senior NIH official pushes MAHA strategy at ADA
- Maritide Phase 2 obesity data
- Danuglipron obesity trial context
Frequently Asked Questions
What newer GLP-1 evidence was top of mind for ADA attendees?
Head-to-head obesity data from SURMOUNT-5 showed tirzepatide cutting weight by 20.2% versus 13.7% with semaglutide at 72 weeks in adults with obesity without type 2 diabetes, reinforcing differentiation beyond first-wave GLP-1 products.
What do NIH budget documents say about research funding pressure?
NIH’s FY 2026 Congressional Justification overview requested a $27.9 billion program level, an $18.1 billion reduction from the prior CR baseline, while a separate NIH Guide notice states enacted Consolidated Appropriations Act funding of $47.5 billion for FY 2026.
Why does this matter for pharma BD and R&D leadership?
Metabolic pipelines still race on GLP-1 and dual-agonist differentiation, but academic partnership capacity and early discovery throughput depend on NIH grant continuity. Teams should scenario-plan around both the enacted appropriation path and the proposed lower budget request.
Primary Sources
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
Deeper reading
Industry reports & whitepapers
- Lilly's Weight-Loss Pill Approved, Sparking Competition with Novo Nordisk — Eli Lilly's daily weight-loss pill received FDA approval, setting the stage for a competitive battle…
- Ensuring Compatibility for GLP-1-based Drugs — The rise of GLP-1 agonists like Semaglutide demands innovative ready-to-use cartridges to enhance de…